Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
05-28 Cumberland Pharmaceuticals Launches Vibativ Injection in China in Strategic Partnership with SciClone Pharmaceuticals Limited CI
25-02-18 Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals Limited Announce the National Medical Products Administration Approval of Cumberland's Vibativ® Injection in China CI
24-06-27 SciClone Pharmaceuticals Limited's Equity Buyback announced on June 6, 2023 has expired. CI
24-06-26 SciClone Pharmaceuticals Limited Announces Retirement of Wang Haixia as Non-Executive Director CI
24-06-20 SciClone Pharmaceuticals Limited(SEHK:6600) dropped from S&P Global BMI Index CI
24-05-16 Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong CI
24-04-18 Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 MT
24-04-01 SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit MT
24-03-28 Sciclone Pharmaceuticals Limited Announces Executive Changes CI
24-03-28 Tranche Update on SciClone Pharmaceuticals Limited's Equity Buyback Plan announced on June 6, 2023. CI
24-03-28 SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
24-03-27 GL China Opportunities Fund IV L.P. and GL China Opportunities Fund IV L.P., managed by GL Capital Group and GL Capital Management GP L.P. agreed to acquire 66.69% stake in SciClone Pharmaceuticals Limited for HKD 7.9 billion. CI
24-01-31 SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3% MT
Manager TitleAgeSince
Chief Executive Officer 61 2020-05-31
Director of Finance/CFO 47 2023-04-27
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 47 2023-04-27
Director/Board Member 61 2020-05-31
Chairman 61 2020-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.47B
+0.05%-0.09%+17.78%-21.38% 62.57B
-3.55%-4.69%+54.37%+191.44% 57.25B
+0.08%+33.30%+33.30%+33.30% 40.76B
+0.68%+8.52%-55.52%-61.99% 36.28B
-0.75%-0.94%+50.51%-33.70% 29.33B
+9.93%+19.63%+119.62%-55.64% 20.68B
-1.82%-3.05%+40.52%+58.28% 20.37B
-1.29%+4.30%-5.33%+125.04% 17.17B
-1.06%-1.24%+49.13%+90.61% 16.04B
Average +0.24%+3.63%+33.82%+36.22% 33.38B
Weighted average by Cap. -0.21%+2.88%+30.11%+37.87%
Logo SciClone Pharmaceuticals (Holdings) Limited
SciClone Pharmaceuticals (Holdings) Ltd is a company principally engaged in the provision of treatment plans for tumors and severe infectious diseases. The Company and its subsidiaries are principally engaged in developing and commercializing a portfolio of marketed products as well as pipelines with potential in their focused therapeutic areas including oncology and severe infection. The Company’s main products comprise Zadaxin, Zometa, Oravig, Angiomax, Endoxan, Holoxan, Cytosafe, Farlutal, Campto and Vizimpro. The Company’s pipeline products include ORSERDU, Vaborem, Vibativ, RRx-001 and Omburtamab. The Company’s products are mainly used in fields such as tumors, urinary tract infections, and skin and soft tissue infections. The Company mainly conducts its businesses in the domestic market.
Employees
1,050
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!